Literature DB >> 43165

Clinical pharmacology of labetalol.

D A Richards, B N Prichard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 43165      PMCID： PMC1429754     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  27 in total

1.  Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.

Authors:  D A Richards; J Tuckman; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

2.  Modification of pressor responses induced by 'cold' [proceedings].

Authors:  J G Maconochie; D A Richards; E P Woodings
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

3.  Effects of labetalol and propranolol on histamine-induced bronchoconstriction in normal subjects.

Authors:  J G Maconochie; E P Woodings; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

4.  Circulatory effects of noradrenaline and adrenaline before and after labetalol.

Authors:  D A Richards; B N Prichard; R Hernández
Journal:  Br J Clin Pharmacol       Date:  1979-04       Impact factor: 4.335

5.  Alpha- and beta-adrenergic receptor blockade in the treatment of hypertension.

Authors:  P A Majid; M K Meeran; M E Benaim; B Sharma; S H Taylor
Journal:  Br Heart J       Date:  1974-06

6.  Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension.

Authors:  B N Prichard; F O Thompson; A J Boakes; A M Joekes
Journal:  Clin Sci Mol Med Suppl       Date:  1975-06

7.  Haemodynamic effects of long-term oral labetalol.

Authors:  R C Edwards; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

8.  Metabolism of labetalol by animals and man.

Authors:  L E Martin; R Hopkins; R Bland
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

9.  Comparison of the effects of labetalol and propranolol in healthy men at rest and during exercise.

Authors:  D A Richards; E P Woodings; J G Maconochie
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

10.  Acute hemodynamic effects of an alpha- and beta-receptor blocking agent (AH 5158) on the systemic and pulmonary circulation at rest and during exercise in hypertensive patients.

Authors:  G Koch
Journal:  Am Heart J       Date:  1977-05       Impact factor: 4.749
View more
  24 in total

1.  Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine.

Authors:  B Tomlinson; F Bompart; B R Graham; J B Liu; B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects.

Authors:  Sze Wa Chan; Miao Hu; Sara Shun Wah Ko; Catherine Wing Yan Tam; Benny Siu Pong Fok; Ophelia Qi Ping Yin; Moses Sing Sum Chow; Brian Tomlinson
Journal:  Eur J Clin Pharmacol       Date:  2012-10-23       Impact factor: 2.953

Review 3.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 4.  Comparison of labetalol with other anti-hypertensive drugs.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

5.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

6.  The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.

Authors:  T C Tham; S Guy; B J McDermott; R G Shanks; J G Riddell
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

7.  Clinical evaluation of labetalol alone and combined with chlorthalidone in essential hypertension: a double-blind multicentre controlled study.

Authors:  A Lechi; S Pomari; R Berto; P Buniotto; A Parrinello; F Marini; L Cogo; A Tomasi; G Baretta
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Transfer of labetalol into amniotic fluid and breast milk in lactating women.

Authors:  N O Lunell; J Kulas; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Clinical pharmacology of carvedilol.

Authors:  B Tomlinson; B N Prichard; B R Graham; R J Walden
Journal:  Clin Investig       Date:  1992

10.  Metabolic and haemodynamic effects of increased circulating adrenaline in man. Effect of labetalol, an alpha and beta blocker.

Authors:  A D Struthers; R Whitesmith; J L Reid
Journal:  Br Heart J       Date:  1983-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.